Altimmune, Inc. (ALT) · Oct 29, 2026 · New debt

Altimmune debt draw adds $10M and extends interest-only period

$10M debt draw — $10.0M funded; interest-only period extended to June 1, 2028

Altimmune’s financing update brings in $10 million and extends interest-only payments to June 2028, supporting its Phase 3 development push.

Altimmune is a late-stage biotech advancing pemvidutide into Phase 3 for MASH while also developing it for alcohol-use and alcohol-associated liver disease; its latest reported cash, cash equivalents and investments totaled $519 million as of June 30, 2026.

The financing milestone was achieved and converts available credit into cash. Altimmune drew $10 million from its existing $125 million Hercules facility after meeting the required clinical and financial milestones. This is supportive for the development program, but not a surprise in direction: the facility and milestone-based tranche were disclosed when the loan was amended in November 2025.

The most useful change is funding flexibility, not the $10 million itself. The draw extends the amortization date and interest-only period to June 1, 2028, reducing near-term repayment pressure while Altimmune runs its registrational PERFORMA Phase 3 trial. 〔0〕

TermFiling figurePrior / comparison
Tranche Three funding (Loan Agreement)$10.0M$125.0M total facility
Interest-only period (Loan Agreement)June 1, 2028—
Minimum Qualified Cash covenant (Loan Agreement)60% of outstanding principal—
Tranche facility charge (Loan Agreement)1.0%—
End-of-term charge (Loan Agreement)6.25%—

The trade-off is additional secured debt and a tighter cash restriction. Altimmune must keep qualified cash at least equal to 60% of outstanding term-loan principal, while paying a 1% facility charge and retaining a 6.25% end-of-term charge. 〔1〕 Those costs and constraints matter, but the filing does not suggest a new liquidity problem; rather, it adds debt capacity to an already well-funded clinical-stage program.

Bottom line: This is a modestly constructive financing update: Altimmune met the milestone, added $10 million of non-equity capital, and pushed repayment pressure well beyond the current Phase 3 buildout. It advances the program, though the facility’s fees and cash covenant make it a funding bridge—not a business-model breakthrough.

What to watch next

RESTORE Phase 2 topline data, second half of 2027

Original filing on SEC EDGAR

More Altimmune, Inc. news

Altimmune debt draw adds $10M and extends interest-only period | ALT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.